Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03142919
Other study ID # 2016-002-00
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date September 7, 2017
Est. completion date December 1, 2020

Study information

Verified date November 2023
Source Laureate Institute for Brain Research, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

LPS Challenge in Individuals with Major Depressive Disorder


Description:

The aim of this project is to understand the biological differences between two distinct subtypes of depression, patients with and without inflammation as defined by c-reactive protein (CRP). Using a double-blinded, parallel group, placebo-controlled design, participants will be phenotyped before and after a low-dose lipopolysaccharide (LPS) challenge designed to perturb the immune system and trigger a transient, mild inflammatory response. This experimental design will allow for the delineation of the homeostatic mechanisms underlying sensitivity to inflammation-related depression. Low-dose LPS has been used by multiple groups to safely induce transient inflammatory responses in humans.


Recruitment information / eligibility

Status Completed
Enrollment 68
Est. completion date December 1, 2020
Est. primary completion date December 1, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: Depressed participants will be required to be in good general health (as evaluated during Visit 1, including EKG) and to be 18-55 years of age. Depressed participants will be required to have symptoms of depression (i.e. a PHQ-9 score =10) and be unmedicated for at least 3 weeks (8 weeks for fluoxetine) or treated with only one anti-depressant medication. Half the depressed participants (N=50) will be required to have a high-sensitivity C-Reactive Protein (CRP) score of =3 mg/L, and half the participants will be required to have a CRP score of =1 mg/L. General Exclusion Criteria: - Pregnancy - Previous history of fainting during blood draws. Medical Conditions: - A history of a head injury with loss of consciousness. - Presence of co-morbid medical conditions not limited to but including cardiovascular (e.g., history of acute coronary event, stroke) and neurological diseases (e.g., Parkinson's disease), as well as pain disorders. - Presence of co-morbid inflammatory disorders such as rheumatoid arthritis or other autoimmune disorders. - Presence of an uncontrolled medical condition that is deemed by the investigators to interfere with the proposed study procedures, or to put the study participant at undue risk. - Presence of chronic infection that may elevate pro-inflammatory cytokines. - Presence of an acute infectious illness or receipt of a vaccination in the two weeks prior to an experimental session. Psychiatric Disorders: - Current severe suicidal ideation or attempt within the past 12 months. - Psychosis - Bipolar disorder - Substance abuse or dependence within the previous 6 months - Age of onset of depression >40 years Contraindications for MRI: - Severe claustrophobia - Bodily implants of unsafe paramagnetic materials such as pace-makers and aneurysm clips. Medications: - Current and/or past regular use of hormone-containing medications (excluding contraceptives) - Current use of non-steroid anti-inflammatory drugs that is deemed by the investigators to potentially confound the results of the study - Current and/or past regular use of immune modifying drugs that target specific immune responses such as TNF antagonists - Current use of analgesics such as opioids or history of addiction to opioids or other analgesics - Current and/or past regular use of cardiovascular medications, including antihypertensive, antiarrhythmic, anti-anginal, and anticoagulant drugs (does not apply where medications are taken for different purpose e.g. anti-hypertensives for migraine). - Evidence of recreational drug use from urine test. - Lifetime use of methamphetamine Health Factors: - BMI > 35 because of the effects of obesity on pro-inflammatory cytokine activity - Clinically significant abnormalities on screening laboratory tests - Abnormal EKG - In addition, participants who on arrival to the study, show any of the following symptoms will not be allowed to complete the study: 1. screening supine systolic blood pressure >140 mmHg or <100 mmHg 2. screening supine diastolic blood pressure >90 mmHg or <60 mmHg 3. 12-lead EKG demonstrating a PR interval > 0.2 msec, QTc >450 or QRS >120 msec If the QTc exceeds 450 msec, or QRS exceeds 120 msec, the EKG will be repeated 2 more times and the median value will be used 4. pulse less than 50 beats/minute or greater than 100 beats/minute 5. temperature greater than 99.5F. Non-English speaking participants: - The majority of the assessments proposed for this study have not been translated from English, thus, non-English speaking volunteers will be excluded.

Study Design


Intervention

Biological:
Lipopolysaccharide
Lipopolysaccharide (LPS) derived from E. Coli group O 113:H10:K negative
Placebo
Saline solution

Locations

Country Name City State
United States Laureate Institute for Brain Research Tulsa Oklahoma

Sponsors (1)

Lead Sponsor Collaborator
Laureate Institute for Brain Research, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Snaith-Hamilton Pleasure Scale (SHAPS) The SHAPS is a 14-item self-administered questionnaire, with each item scored from 1-4 (strongly agree through strongly disagree; range 14-56), with higher scores indicating greater anticipatory, not consummatory, anhedonia. Disagreement (i.e. score of 3 or 4) on at least three items is defined as indicating clinically significant anhedonia. Baseline, 1 hour, 2-hours, 3-hours, 4-hours, 6 hours, 24 hours, one week
Secondary Change in Montgomery-Asberg Depression Rating Scale (MADRS) Clinician-administered depression rating scale with scores ranging from 0-60. Higher scores indicate more depression. Baseline, 6 hours, 24 hours, one week
Secondary Change in Interleukin 6 (IL-6) protein levels pro-inflammatory cytokine measured in pg/mL Baseline, 1 hour, 2-hours, 3-hours, 6 hours, 24 hours, one week
Secondary Change in Interleukin 10 (IL-10) protein levels Measure of systemic inflammation in pg/mL Baseline, 1 hour, 2-hours, 3-hours, 6 hours, 24 hours, one week
Secondary Change in Tumor Necrosis Factor (TNF) protein levels Measure of systemic inflammation in pg/mL Baseline, 1 hour, 2-hours, 3-hours, 6 hours, 24 hours, one week
Secondary Change in Blood Oxygenation Level Dependent signal (BOLD) Ventral Striatum Beta-weights for the average activity across the ventral striatum Baseline line; 2-3 hours
Secondary Change in Blood Oxygenation Level Dependent signal (BOLD) Insula Beta-weights for the average activity across the insula Baseline line; 2-3 hours
Secondary Change in Temperature Body temperature measured in degrees Fahrenheit. Baseline, 1 hour, 2-hours, 3-hours, 4-hours, 6 hours, 24 hours, one week
See also
  Status Clinical Trial Phase
Recruiting NCT05537558 - Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
Terminated NCT02192099 - Open Label Extension for GLYX13-C-202, NCT01684163 Phase 2
Recruiting NCT05547035 - Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders N/A
Terminated NCT02940769 - Neurobiological Effects of Light on MDD N/A
Recruiting NCT05892744 - Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression Phase 4
Recruiting NCT05537584 - SMART Trial to Predict Anhedonia Response to Antidepressant Treatment Phase 4
Active, not recruiting NCT05061706 - Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder Phase 3
Completed NCT04479852 - A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder Phase 2
Recruiting NCT04032301 - Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans Phase 1
Recruiting NCT05527951 - Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study N/A
Completed NCT03511599 - Cycloserine rTMS Plasticity Augmentation in Depression Phase 1
Recruiting NCT04392947 - Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation N/A
Recruiting NCT05895747 - 5-HTP and Creatine for Depression R33 Phase Phase 2
Recruiting NCT05273996 - Predictors of Cognitive Outcomes in Geriatric Depression Phase 4
Recruiting NCT05813093 - Interleaved TMS-fMRI in Ultra-treatment Resistant Depression N/A
Recruiting NCT05135897 - The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
Enrolling by invitation NCT04509102 - Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder Early Phase 1
Recruiting NCT06145594 - EMA-Guided Maintenance TMS for Depression N/A
Recruiting NCT06026917 - Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET) Phase 4
Recruiting NCT04422652 - Combination of Novel Therapies for CKD Comorbid Depression Phase 2